Stomach perforation-induced general occlusion/occlusion-like syndrome and stable gastric pentadecapeptide BPC 157 therapy effect

Table 2 Relative volume of the stomach of the heart, azygos vein, in rats at 5 min and 15 min following stomach perforation

0 min	5 min	5 min	15 min
Relative volume (healthy/perforation, %) of the stomach in rats immediately after perforation	Application of the 1 mL/rat through the perforated defect in the injured stomach at 5 min following perforation	Relative volume (healthy/perforation, healthy/perforation + therapy, %) of the stomach, in rats at 5 min and 15 min following stomach perforation
Relative volume (healthy/perforation, %) of the stomach, mean ± SD	Medication	Relative volume (healthy/perforation + therapy, %) of the stomach, mean ± SD
100 ± 3	Saline 5 mL/kg (control)	114 ± 2a,b	118 ± 2a,b
100 ± 2	BPC 157 10 μg/kg	87 ± 5a,b,c	76 ± 8a,b,c
101 ± 2	BPC 157 10 ng/kg	81 ± 7a,b,c	79 ± 9a,b,c

^aP < 0.05, at least vs healthy.

^bP < 0.05, at least vs immediately after perforation.

^cP < 0.05, at least vs corresponding control at the time of the assessment.

Relative volume (healthy/perforation, healthy/perforation + therapy, %) of the stomach of the heart, azygos vein, in rats at 5 min and 15 min following stomach perforation. Saline (5 mL/kg, control) or BPC 157 (10 μg/kg and 10 ng/kg) were given at 5 min after perforation.